Trial Profile
A Randomized, Double Blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Efficacy and Safety of Roniciclib in Subjects With Extensive-stage Disease Small Cell Lung Cancer (SCLC) Who Are Receiving Cisplatin + Etoposide or Carboplatin + Etoposide as First-line Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Roniciclib (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms CONCEPT-SCLC
- Sponsors Bayer
- 12 Jan 2019 Results published in the Journal of Thoracic Oncology
- 11 Apr 2017 This trial has been suspended in Poland as per European Clinical Trials Database record.
- 11 Oct 2016 Primary endpoint (Progression-free survival) has not been met as per results presented at the 41st European Society for Medical Oncology Congress